Core Viewpoint - The company has entered into an exclusive licensing and equity cooperation agreement with Solstice Oncology to develop and commercialize its clinical-stage asset HBM4003 outside Greater China, which is expected to enhance its global collaboration network and maximize the scientific and commercial value of its technology platform [1][2] Group 1 - The agreement includes upfront payments exceeding $105 million, comprising a $50 million upfront payment, a $5 million recent payment, and over $50 million in equity issued by Solstice Oncology [1] - The company is also eligible for up to approximately $1.1 billion in additional milestone payments based on development, regulatory, and commercial achievements, as well as tiered royalties based on net sales of HBM4003 outside Greater China [1] - This collaboration aims to accelerate the global development and commercialization of HBM4003, allowing the company to deeply engage in and drive the global development process of the asset [2]
和铂医药-B(02142.HK)与Solstice Oncology达成独家授权及股权合作 超1.05亿美元前期对价+11亿美元里程碑